Vertex Pharmaceuticals Inc. diskutieren
Vertex Pharmaceuticals Inc.
WKN: 882807 / Symbol: VRTX / Name: Vertex / Aktie / Biotechnologie & medizinische Forschung / Large Cap /
372,90 €
1,56 %
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target raised by analysts at HC Wainwright from $390.00 to $397.00. They now have a "buy" rating on the stock.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $380.00 price target on the stock.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $415.00 price target on the stock.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) was downgraded by analysts at Canaccord Genuity Group Inc. from a "hold" rating to a "sell" rating. They now have a $379.00 price target on the stock, up previously from $332.00.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target raised by analysts at Cantor Fitzgerald from $415.00 to $440.00. They now have an "overweight" rating on the stock.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) was downgraded by analysts at Robert W. Baird from a "neutral" rating to an "underperform" rating. They now have a $325.00 price target on the stock.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $442.00 to $559.00. They now have a "buy" rating on the stock.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target raised by analysts at Truist Financial Co. from $456.00 to $508.00. They now have a "buy" rating on the stock.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target raised by analysts at JPMorgan Chase & Co. from $390.00 to $438.00. They now have an "overweight" rating on the stock.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target raised by analysts at HC Wainwright from $397.00 to $457.00. They now have a "buy" rating on the stock.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its "outperform" rating re-affirmed by analysts at William Blair.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target raised by analysts at Barclays PLC from $446.00 to $472.00. They now have an "overweight" rating on the stock.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target raised by analysts at Wells Fargo & Company from $500.00 to $540.00. They now have an "overweight" rating on the stock.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $440.00 price target on the stock.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $515.00 price target on the stock.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $440.00 price target on the stock.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Ratings data for VRTX provided by MarketBeat
Neueste Beiträge
Citigroup_Inc_ in Ford Motor Co. diskutieren